Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors

Molecular and Cellular Biology

Volumn 19, Issue 3, 1999, Pages 1775-1783

  Parry, David ^a   Mahony, Daniel ^a   Wills, Ken ^a   Lees, Emma ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D; CYCLIN DEPENDENT KINASE;

ARTICLE; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; ENZYME SUBUNIT; HUMAN; HUMAN CELL; MITOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 0032980425     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.19.3.1775     Document Type: Article

References (53)

1. Ink4 and retinoblastoma tumour-suppressor genes occur in distinct sub-sets of human cancer cell lines. Int. J. Cancer 61:115-120.
2. Alcorta, D., Y. Xiong, D. Phelps, G. Hannon, D. Beach, and J. Barrett. 1996. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc. Natl. Acad. Sci. USA 93:13742-13747.
3. Bates, S., L. Bonetta, D. MacAllan, D. Parry, A. Holder, C. Dickson, and G. Peters. 1994. CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct set of the cyclin-dependent kinases that associate with cyclin D1. Oncogene 9:71-79.
4. Bates, S., D. Parry, L. Bonetta, K. Vousden, C. Dickson, and G. Peters. 1994. Absence of cyclin D/cdk complexes in cells lacking functional retinoblastoma protein. Oncogene 9:1633-1640.
5. Brookes, S., G. Lammie, E. Schuuring, C. de Boer, R. Michalides, C. Dickson, and G. Peters. 1993. Amplified region of chromosome band 11q13 in breast and squamous cell carcinomas encompasses three CpG islands telomeric of FGF3, including the expressed gene EMS1. Genes Chromosomes Cancer 6:222-231.
6. Dai, K., R. Kobayashi, and D. Beach. 1996. Physical interaction of mammalian CDC37 with CDK4. J. Biol. Chem. 271:22030-22034.
7. El-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
8. Gu, Y., C. W. Turck, and D. O. Morgan. 1993. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 366:707-710.
9. Guan, K.-L., C. W. Jenkins, Y. Li, M. A. Nichols, X. Wu, C. L. O'Keefe, A. G. Matera, and Y. Xiong. 1994. Growth suppression by p18, a p16INK4/MTS1 and p14INK4B/MTS2-related CDK6 inhibitor correlates with wild-type pRb function. Genes Dev. 8:2939-2952.
10. INK4d, a p16-related inhibitor specific to CDK6 and CDK4. Mol. Biol. Cell 7:57-70.
11. Hall, M., and G. Peters. 1996. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv. Cancer Res. 68:67-108.
12. Hannon, G. J., and D. Beach. 1994. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 371:257-261.
13. Hara, E., R. Smith, D. Parry, H. Tahara, S. Stone, and G. Peters. 1996. Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol. Cell. Biol. 16:859-867.
14. Harlow, E., and D. Lane. 1988. Antibodies: a laboratory manual. Cold Spring Harbor Press, Cold Spring Harbor, N.Y.
15. Harper, J. W., G. R. Adami, N. Wei, K. Keyomarsi, and S. J. Elledge. 1993. The p21 Cdk-interactting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816.
16. Harper, J. W., S. J. Elledge, K. Keyomarsi, B. Dynlacht, L.-H. Tsai, P. Zhang, S. Dobrowolski, C. Bai, L. Connell-Crowley, E. Swindell, M. P. Fox, and N. Wei. 1995. Inhibition of cyclin-dependent kinases by p21. Mol. Biol. Cell 6:387-400.
17. He, J., J. R. Allen, V. P. Collins, T. M. Allalunis, R. Godbout, R. R. Day, and C. D. James. 1994. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res. 54:5804-5807.
18. Hirai, H., M. F. Roussel, J.-Y. Kato, R. A. Ashmun, and C. J. Sherr. 1995. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol. Cell. Biol. 15:2672-2681.
19. Koh, J., G. H. Enders, B. D. Dynlacht, and E. Harlow. 1995. Tumor-derived p16 alleles encoding proteins defective in cell cycle inhibition. Nature 375: 506-510.
20. LaBaer, J., M. Garrett, L. Stevenson, J. Slingerland, C. Sandhu, H. Chou, A. Fattaey, and E. Harlow. 1997. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 11:847-862.
21. Lammie, G., V. Fantl, R. Smith, E. Schuuring, S. Brookes, R. Michalides, C. Dickson, A. Arnold, and G. Peters. 1991. D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene 6:439-444.
22. KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev. 9:639-649.
23. Liu, Y., J. Martindale, M. Gorospe, and N. Holbrook. 1996. Regulation of p21WAF1/CIP1 expression through mitogen-activated protein kinase signaling pathway. Cancer Res. 56:31-35.
24. 1 control in retinoblastoma gene-deficient cells independently of cdk4 activity. Mol. Cell. Biol. 15:2600-2611.
25. Lukas, J., D. Parry, L. Aagard, D. J. Mann, J. Bartkova, M. Strauss, G. Peters, and J. Bartek. 1995. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumor suppressor p16. Nature 375:503-506.
26. Maelandsmo, G., J. Berner, V. Florenes, A. Forus, E. Hovig, O. Fodstad, and O. Myklebost. 1995. Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas - relationship to amplification and mRNA levels of CDK4 and CCND1. Br. J. Cancer 72:393-398.
27. Mahony, D., D. Parry, and E. Lees. 1998. Active cdk6 complexes are predominantly nuclear and represent only a minority of the cdk6 in T cells. Oncogene 16:603-611.
28. Matsuoka, S., M. C. Edwards, C. Bai, S. Parker, P. Zhang, A. Baldini, J. W. Harper, and S. J. Elledge. 1995. p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev. 9:650-662.
29. PSK-J3/cdk4) for mammalian D type cyclins. Cell 71: 323-334.
30. Matsushime, H., D. E. Quelle, S. A. Shurtleff, M. Shibuya, C. J. Sherr, and J.-Y. Kato. 1994. D-type cyclin-dependent kinase activity in mammalian cells. Mol. Cell. Biol. 14:2066-2076.
31. Matsushime, H., M. F. Roussel, R. A. Ashmun, and C. J. Sherr. 1991. Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell 65:701-713.
32. 1 kinase activity for cdk6, a novel cyclin D partner. Mol. Cell. Biol. 14:2077-2086.
33. Musgrove, E., A. Swarbrick, C. S. Lee, A. L. Cornish, and R. Sutherland. 1998. Mechanisms of cyclin-dependent kinase inactivation by progestins. Mol. Cell. Biol. 18:1812-1825.
34. Noda, A., Y. Ning, S. F. Venable, O. M. Pereira-Smith, and J. R. Smith. 1994. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res. 211:90-98.
35. INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 9:3375-3378.
36. Palmero, I., B. McConnell, D. Parry, S. Brookes, E. Hara, S. Bates, P. Jat, and G. Peters. 1997. Accumulation of p16INK4a in mouse fibroblasts as a function of replicative senescence and not of retinoblastoma gene status. Oncogene 15:495-503.
37. Pardee, A. 1974. A restriction point for control of normal animal cell proliferation. Proc. Natl. Acad. Sci. USA 71:1286-1290.
38. INK4/MTS1 tumour suppressor gene product. EMBO J. 14:503-511.
39. Parry, D., and G. Peters. 1996. Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma. Mol. Cell. Biol. 16:3844-3852.
40. Polyak, K., M. H. Lee, B. H. Erdjument, A. Koff, J. M. Roberts, P. Tempst, and J. Massague. 1994. Cloning of p27Kipl, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59-66.
41. Schmidt, E. E., K. Ichimura, G. Reifenberger, and V. P. Collins. 1994. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res. 54:6321-6324.
42. Serrano, M., G. J. Hannon, and D. Beach. 1993. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707.
43. Sewing, A., B. Wiseman, A. Lloyd, and H. Land. 1997. High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. Mol. Cell. Biol. 17:5588-5597.
44. Sherr, C. J. 1996. Cancer cell cycles. Science 274:1672-1677.
45. Sherr, C. J. 1994. G1 phase progression: cycling on cue. Cell 79:551-555.
46. 1 cyclins. Cell 73:1059-1065.
47. cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev. 10:1491-1502.
48. Toyoshima, H., and T. Hunter. 1994. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78:67-74.
49. Wang, J., K. Guo, K. Wills, and K. Walsh. 1997. Rb functions to inhibit apoptosis during myocyte differentiation. Cancer Res. 57:351-354.
50. Wolfel, T., M. Hauer, J. Schneider, M. Serrano, C. Wolfel, E. Klehmann-Hieb, E. De Plaen, T. Hankeln, K. Meyer zum Buschenfelde, and D. Beach. 1995. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281-1284.
51. Woods, D., D. Parry, H. Cherwinski, E. Bosch, E. Lees, and M. McMahon. 1997. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol. Cell. Biol. 17:5598-5611.
52. Xiong, Y., G. J. Hannon, H. Zhang, D. Casso, R. Kobayashi, and D. Beach. 1993. p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704.
53. Xiong, Y., H. Zhang, and D. Beach. 1992. D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 71:505-514.